2018
Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia
Sullivan R, Abraham A, Simpson C, Olear E, Carpenter T, Deng Y, Chen C, Insogna KL. Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia. Calcified Tissue International 2018, 102: 666-670. PMID: 29383408, PMCID: PMC5957766, DOI: 10.1007/s00223-017-0382-0.Peer-Reviewed Original ResearchConceptsLevels of FGF23Nasal salmon calcitoninSalmon calcitoninStudy drugVisit 2Day 2Levels of PTHPrincipal outcome variableTmP/GFRSingle subcutaneous dosePlacebo nasal sprayNasal calcitoninSerum calciumSubcutaneous doseVisit 4Dihydroxyvitamin DSerum phosphorusVisit 3Final doseVisit 1Nasal sprayClinical trialsSerial measurementsDrug doseFGF23 production
1985
Elevated Production Rate of 1,25-Dihydroxyvitamin D in Patients with Absorptive Hypercalciuria*
INSOGNA K, BROADUS A, DREYER B, ELLISON A, GERTNER J. Elevated Production Rate of 1,25-Dihydroxyvitamin D in Patients with Absorptive Hypercalciuria*. The Journal Of Clinical Endocrinology & Metabolism 1985, 61: 490-495. PMID: 2991323, DOI: 10.1210/jcem-61-3-490.Peer-Reviewed Original ResearchConceptsAbsorptive hypercalciuriaMicrograms/dayNormal subjectsMetabolic clearancePlasma radioactivityMean steady-state concentrationMCR valuesHypercalciuric patientsCalcium intakeDihydroxyvitamin DSerial measurementsHypercalciuriaPatientsConstant infusionConflicting resultsClearanceSteady-state concentrations